Quality of heart failure care in managed Medicare and Medicaid patients in North Carolina

American Journal of Cardiology

Volumn 93, Issue 6, 2004, Pages 714-718

  Bertoni, Alain G ^a   Duren Winfield, Vanessa ^b   Ambrosius, Walter T ^b   McArdle, Jill ^b   Sueta, Carla A ^b   Massing, Mark W ^b   Peacock, Sharon ^b   Davis, Jennifer ^b   Croft, Janet B ^b   Goff Jr , David C ^b  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; ISOSORBIDE; NITRATE; SPIRONOLACTONE; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HEALTH CARE QUALITY; HEART LEFT VENTRICLE FAILURE; HOSPITAL PATIENT; HUMAN; INSURANCE; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICAID; MEDICAL RECORD; MEDICARE; NURSE; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; SIDE EFFECT; SYSTOLE; TREATMENT CONTRAINDICATION; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; GUIDELINE ADHERENCE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MANAGED CARE PROGRAMS; MEDICAID; MEDICAL RECORDS; MEDICARE; MIDDLE AGED; NORTH CAROLINA; QUALITY ASSURANCE, HEALTH CARE; RETROSPECTIVE STUDIES; TOTAL QUALITY MANAGEMENT;

EID: 12144287815     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.11.053     Document Type: Article

References (27)

1. Senni M., Tribouilloy C.M., Rodeheffer R.J., Jacobsen S.J., Evans J.M., Bailey K.R. Congestive heart failure in the community trends in incidence and survival in a 10-year period. Arch Intern Med. 159:1999;29-34.
2. American Heart Association. Heart disease and stroke statistics - 2003 update. Dallas, TX: American Heart Association, 2002.
3. Cohn J.N., Archibald D.G., Ziesche S., Franciosa J.A., Harston W.E., Tristani F.E. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 314:1986;1547-1552.
4. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
5. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 334:1996;1349-1355.
6. Hjalmarson A., Goldstein S., Fagerberg B., Wedel H., Waagstein F., Kjekshus J., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 283:2000;1295-1302.
7. Lechat P., Packer M., Chalon S., Cucherat M., Arab T., Boissel J.P. Clinical effects of beta-adrenergic blockade in chronic heart failure a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation. 98:1998;1184-1191.
8. Garg R., Yusuf S. Overview of randomized trials of angiotensin- converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 273:1995;1450-1456.
9. Hunt S.A., Baker D.W., Chin M.H., Cinequegrani P., Feldmanmd A.M., Francis G.S., et al. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the Adult Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in Collaboration With the International Society for Heart and Lung Transplantation, endorsed by the Heart Failure Society of America. Circulation. 104:2001;2996-3007.
10. Heart Failure Society of America. HFSA guidelines for the management of patients with heart failure due to left ventricular systolic dysfunction - pharmacological approaches. Congestive Heart Fail 2000;6:11-39.
11. Baker D.W., Fitzgerald D., Moore C.L. Quality of care for Medicare patients hospitalized with heart failure in rural Georgia. South Med J. 92:1999;782-789.
12. Philbin E.F. Factors determining angiotensin-converting enzyme inhibitor underutilization in heart failure in a community setting. Clin Cardiol. 21:1998;103-108.
13. Bungard T.J., McAlister F.A., Johnson J.A., Tsuyuki R.T. Underutilization of ACE inhibitors in patients with congestive heart failure. Drugs. 61:2001;2021-2033.
14. Philbin E.F., Rocco T.A., Lindenmuth N.W., Ulrich K., Jenkins P.L. Systolic versus diastolic heart failure in community practice clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med. 109:2000;683-685.
15. Simko R.J., Stanek E.J. Treatment patterns for heart failure in a primary care environment. Am J Manag Care. 3:1997;1669-1676.
16. Stafford R.S., Radley D.C. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 41:2003;56-61.
17. Krumholz H.M., Wang Y., Parent E.M., Mockalis J., Petrillo M., Radford M.J. Quality of care for elderly patients hospitalized with heart failure. Arch Intern Med. 157:1997;2242-2247.
18. Howard P.A., Shireman T.I., Dhingra A., Ellerbeck E.F., Fincham J.E. Patterns of ACE inhibitor use in elderly medicaid patients with heart failure. Am J Geriatr Cardiol. 11:2002;287-294.
19. Medicare + Choice Quality Review Organization. Quality Assessment Performance Improvement Instructional Guide. Baltimore, MD: Centers for Medicare and Medicaid Services (CMS), 2001.
20. Centers for Medicare and Medicaid Services. Health Plans Operational Policy Letter #2000.129. Centers for Medicare and Medicaid Services. 5-29-2003.
21. Jencks S.F., Huff E.D., Cuerdon T. Change in the quality of care delivered to Medicare beneficiaries, 1998-1999 to 2000-2001. JAMA. 289:2003;305-312.
22. Goff D.C. Jr, Pandey D.K., Chan F.A., Ortiz C., Nichaman M.Z. Congestive heart failure in the United States is there more than meets the I (CD code)? The Corpus Christi Heart Project. Arch Intern Med. 160:2000;197-202.
23. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 341:1999;709-717.
24. Jong P., Vowinckel E., Liu P.P., Gong Y., Tu J.V. Prognosis and determinants of survival in patients newly hospitalized for heart failure a population-based study. Arch Intern Med. 162:2002;1689-1694.
25. Cowie M.R., Wood D.A., Coats A.J., Thompson S.G., Suresh V., Poole-Wilson P.A. Survival of patients with a new diagnosis of heart failure a population based study. Heart. 83:2000;505-510.
26. Luzier A.B., Forrest A., Feuerstein S.G., Schentag J.J., Izzo J.L. Jr. Containment of heart failure hospitalizations and cost by angiotensin- converting enzyme inhibitor dosage optimization. Am J Cardiol. 86:2000;519-523.
27. Najib M.M., Goldberg Arnold R.J., Kaniecki D.J., Pettit K.G., Roth D., Antell L. Medical resource use and costs of congestive heart failure after carvedilol use. Heart Dis. 4:2002;70-77.